ITI Pharma and Healthcare Fund
Sectoral-PharmaVery HighOPEN-ENDED
- NAV as on 24 Sep 2026
- ₹18.31-0.73%1 day
- Return since launch
- 13.4%
- 52-week range
- ₹14.50 — ₹18.45
- AUM
- ₹276 Cr
ITI Pharma and Healthcare Fund is a Sectoral-Pharma equity fund from ITI Mutual Fund with ₹276 Cr under management, launched in 2021. Over three years it has returned 13.7% a year, against 21.1% for its category. The expense ratio is 2.63% and the SEBI riskometer reading is Very High.
Performance
ITI Pharma and Healthcare Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +13.6% against +17.6% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 25.2% | +6.3 pts | 18.9% | 26.8% |
| 2Y | 12.2% | −4.8 pts | 17.1% | 15.4% |
| 3Y | 13.7% | −7.4 pts | 21.1% | 16.1% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 1.4% | +0.4 pts | 1.0% | 0.9% |
| 3M | 6.9% | −0.6 pts | 7.5% | 7.1% |
| 6M | 21.4% | −0.5 pts | 21.9% | 20.5% |
| 1Y | 13.6% | −5.3 pts | 18.9% | 17.6% |
| 2Y | 4.0% | −4.3 pts | 8.3% | 6.9% |
| 3Y | 19.2% | −1.9 pts | 21.1% | 20.6% |
Since launch (18 Oct 2021): 13.4%
Calendar-year returns
Category average-8.7%
31.6%
40.9%
-10.0%
Show as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -10.0% | −7.9 pts | -2.0% |
| 2024 | 40.9% | 0.0 pts | 40.9% |
| 2023 | 31.6% | −4.6 pts | 36.2% |
| 2022 | -8.7% | −0.4 pts | -8.3% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.62%
Expense ratio as on 23 Sep 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 2.10%
- Brokerage
- 0.08%
- Transaction charges
- 0.00%
- Statutory levies
- 0.44%
- Exit load
- Exit load of 0.50%, if redeemed within 3 months.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- NIFTY Healthcare TRI.
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Very High
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
| Ratio | Fund | Category avg | Read as |
|---|---|---|---|
| Alpha | -3.49 | 0.74 | Return earned above what the benchmark alone would have given. Higher is better. |
| Beta | 0.99 | 0.93 | How hard the fund moves when the market moves. Under 1 is steadier than the market. |
| Sharpe | 0.80 | 1.05 | Return earned for each unit of total risk taken. Higher is better. |
| Sortino | 1.13 | 1.63 | Return earned for each unit of downside risk. Higher is better. |
| Std. deviation | 16.40 | 15.68 | How widely monthly returns have varied around their own average. Lower is steadier. |
| Average of 5 category peers | |||
Portfolio
ITI Pharma and Healthcare Fund portfolio
Portfolio as of 31 Aug 2026
Asset allocation
- Equity99.3%
- Other0.7%
Market cap split
- Large36.8%
- Mid40.3%
- Small23.0%
- P/E
- 48.55
- P/B
- 6.12
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 12.58% | ₹34.76 Cr | +14.25% | +11.12% | +10.60% |
| Divi's Laboratories Ltd. | Healthcare | 9.23% | ₹25.50 Cr | +8.43% | +9.01% | +8.38% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.72% | ₹15.79 Cr | +6.20% | +6.62% | +5.96% |
| Max Healthcare Institute Ltd. | Healthcare | 4.84% | ₹13.37 Cr | +4.90% | +5.94% | +5.89% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 4.75% | ₹13.13 Cr | +4.90% | +5.17% | +4.53% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 4.31% | ₹11.91 Cr | +3.98% | +1.83% | +2.02% |
| Cipla Ltd. | Healthcare | 4.22% | ₹11.67 Cr | +3.42% | +1.75% | +2.33% |
| Laurus Labs Ltd. | Healthcare | 4.02% | ₹11.11 Cr | +5.06% | +2.01% | +1.33% |
| Aurobindo Pharma Ltd. | Healthcare | 3.97% | ₹10.96 Cr | +4.28% | +4.45% | +3.43% |
| Mankind Pharma Ltd. | Healthcare | 3.31% | ₹9.15 Cr | +1.95% | +1.98% | +2.97% |
| Neuland Laboratories Ltd. | Healthcare | 3.18% | ₹8.79 Cr | +3.00% | +2.70% | +2.36% |
| Cohance Lifesciences Ltd. | Healthcare | 3.10% | ₹8.57 Cr | +2.65% | +2.04% | +4.31% |
| Global Health Ltd. | Healthcare | 2.98% | ₹8.23 Cr | — | — | — |
| Alkem Laboratories Ltd. | Healthcare | 2.92% | ₹8.06 Cr | +2.88% | +3.17% | +2.91% |
| Fortis Healthcare Ltd. | Healthcare | 2.82% | ₹7.80 Cr | +3.02% | +3.85% | +3.87% |
| Lupin Ltd. | Healthcare | 2.43% | ₹6.71 Cr | +3.53% | +3.74% | +3.01% |
| Abbott India Ltd. | Healthcare | 1.97% | ₹5.43 Cr | +2.03% | +2.26% | +2.34% |
| Ipca Laboratories Ltd. | Healthcare | 1.92% | ₹5.30 Cr | +1.44% | +1.55% | +1.27% |
| Sai Life Sciences Ltd. | Healthcare | 1.59% | ₹4.40 Cr | +1.63% | +1.78% | +1.65% |
| Shilpa Medicare Ltd. | Healthcare | 1.59% | ₹4.39 Cr | +1.04% | +0.75% | +0.92% |
| Healthcare Global Enterprises Ltd. | Healthcare | 1.55% | ₹4.29 Cr | +1.17% | +1.23% | +1.87% |
| Poly Medicure Ltd. | Healthcare | 1.50% | ₹4.14 Cr | +0.68% | +0.68% | — |
| Aster DM Quality Care Ltd. | Healthcare | 1.47% | ₹4.05 Cr | +1.79% | +3.16% | +3.30% |
| Piramal Pharma Ltd. | Healthcare | 1.32% | ₹3.65 Cr | +1.24% | +1.15% | — |
| Shaily Engineering Plastics Ltd. | Materials | 1.25% | ₹3.46 Cr | +1.47% | +0.99% | — |
| company:19970 | Healthcare | 1.25% | ₹3.45 Cr | — | — | — |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 1.15% | ₹3.18 Cr | +1.23% | +2.05% | +0.78% |
| company:14273 | Healthcare | 1.05% | ₹2.90 Cr | — | — | — |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 1.02% | ₹2.81 Cr | +0.86% | +1.07% | +0.97% |
| Linde India Ltd. | Chemicals | 0.99% | ₹2.74 Cr | +1.30% | +1.30% | +0.88% |
| Rainbow Children's Medicare Ltd. | Healthcare | 0.93% | ₹2.57 Cr | +1.05% | +1.08% | +1.33% |
| Biocon Ltd. | Healthcare | 0.87% | ₹2.41 Cr | +1.26% | +1.33% | +0.68% |
| Supriya Lifescience Ltd. | Healthcare | 0.81% | ₹2.23 Cr | +1.03% | +0.75% | +0.96% |
| company:15608 | Healthcare | 0.74% | ₹2.04 Cr | — | — | — |
| Others | Others | 0.73% | ₹1.96 Cr | +1.99% | +1.05% | +2.17% |
| Zydus Lifesciences Ltd. | Healthcare | 0.71% | ₹1.95 Cr | +0.76% | +0.70% | +0.62% |
| Caplin Point Laboratories Ltd. | Healthcare | 0.61% | ₹1.69 Cr | +0.48% | +0.80% | +0.91% |
| Syngene International Ltd. | Healthcare | 0.60% | ₹1.66 Cr | +0.41% | +0.33% | +0.47% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Others | 2.11% | 0.73% | -1.38% |
| Divi's Laboratories Ltd. | 7.97% | 9.23% | +1.26% |
| company:19970 | 0.00% | 1.25% | +1.25% |
| company:14273 | 0.00% | 1.05% | +1.05% |
| Medplus Health Services Ltd. | 0.88% | 0.00% | -0.88% |
| company:15608 | 0.00% | 0.74% | +0.74% |
| Venus Pipes & Tubes Ltd. | 0.69% | 0.00% | -0.69% |
| Sun Pharmaceutical Industries Ltd. | 13.26% | 12.58% | -0.68% |
| Bharat Dynamics Ltd. | 0.47% | 0.00% | -0.47% |
| Yes Bank Ltd. | 0.46% | 0.00% | -0.46% |
| Shilpa Medicare Ltd. | 1.15% | 1.59% | +0.44% |
| Ipca Laboratories Ltd. | 1.50% | 1.92% | +0.42% |
| Lupin Ltd. | 2.82% | 2.43% | -0.39% |
| Healthcare Global Enterprises Ltd. | 1.21% | 1.55% | +0.34% |
| Apollo Hospitals Enterprise Ltd. | 6.05% | 5.72% | -0.33% |
| Sai Life Sciences Ltd. | 1.32% | 1.59% | +0.27% |
| Cipla Ltd. | 4.43% | 4.22% | -0.21% |
| Max Healthcare Institute Ltd. | 5.05% | 4.84% | -0.21% |
| Laurus Labs Ltd. | 4.21% | 4.02% | -0.19% |
| Neuland Laboratories Ltd. | 3.03% | 3.18% | +0.15% |
| Aurobindo Pharma Ltd. | 3.84% | 3.97% | +0.13% |
| Rainbow Children's Medicare Ltd. | 1.05% | 0.93% | -0.12% |
| Aster DM Quality Care Ltd. | 1.35% | 1.47% | +0.12% |
| Linde India Ltd. | 1.10% | 0.99% | -0.11% |
| Supriya Lifescience Ltd. | 0.92% | 0.81% | -0.11% |
| Dr. Reddy's Laboratories Ltd. | 4.41% | 4.31% | -0.10% |
| Glaxosmithkline Pharmaceuticals Ltd. | 0.93% | 1.02% | +0.09% |
| Torrent Pharmaceuticals Ltd. | 4.84% | 4.75% | -0.09% |
| Mankind Pharma Ltd. | 3.39% | 3.31% | -0.08% |
| Biocon Ltd. | 0.95% | 0.87% | -0.08% |
| Abbott India Ltd. | 1.90% | 1.97% | +0.07% |
| Caplin Point Laboratories Ltd. | 0.54% | 0.61% | +0.07% |
| Cohance Lifesciences Ltd. | 3.04% | 3.10% | +0.06% |
| Glenmark Pharmaceuticals Ltd. | 1.09% | 1.15% | +0.06% |
| Piramal Pharma Ltd. | 1.27% | 1.32% | +0.05% |
| Fortis Healthcare Ltd. | 2.79% | 2.82% | +0.03% |
| Poly Medicure Ltd. | 1.52% | 1.50% | -0.02% |
| Shaily Engineering Plastics Ltd. | 1.23% | 1.25% | +0.02% |
| Syngene International Ltd. | 0.61% | 0.60% | -0.01% |
| Zydus Lifesciences Ltd. | 0.72% | 0.71% | -0.01% |
| Alkem Laboratories Ltd. | 2.92% | 2.92% | 0.00% |
| Global Health Ltd. | 2.98% | 2.98% | 0.00% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹3,579 Cr | 2.19% | 27.6% | 18.0% | 20.3% |
 ICICI Prudential Healthcare Fund | ₹6,996 Cr | 2.07% | 14.4% | 14.4% | 19.6% |
 SBI Healthcare Opportunities Fund | ₹5,796 Cr | 1.99% | 33.3% | 20.2% | 22.4% |
 Mirae Asset Healthcare Fund | ₹3,555 Cr | 2.03% | 31.0% | 18.9% | 20.0% |
 UTI Healthcare Fund | ₹1,444 Cr | 2.21% | 30.9% | 19.5% | 21.3% |
 LIC MF Healthcare Fund | ₹103 Cr | 2.67% | 28.6% | 17.0% | 18.0% |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
Fund managers
- Animesh SinghPost Graduate Diploma in Management, Bachelor of Honours -(Economics) CFA - USA Certification.Prior to joining the ITI AMC, he was associated with Julius Baer wealth Advisor, Centrum Wealth, Nippon Life India Asset Management Ltd, Reliance Portfolio Management Services, KSBL and SSKI Securities.
- Nilay DalalMr. Nilay holds a degree in B.E (Computer) from D.J Sanghvi College of Engg & masterâs in management studies in KJ Somaiya Institute of Management Studies & Research.Prior to joining ITI Mutual Fund, he has with Axis Asset Management Company, SBI Life Insurance Company Ltd & MAQ Software Pvt Ltd.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
₹
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months21.45% absolute | ₹60,000 | ₹72,870 | 21.45% | |
| 1 year13.56% annualised | ₹1,20,000 | ₹1,29,190 | 7.66% | |
| 3 years19.24% annualised | ₹3,60,000 | ₹4,89,793 | 36.05% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.
What is the NAV of ITI Pharma and Healthcare Fund?
The NAV of ITI Pharma and Healthcare Fund is ₹18.31 as on 24 Sep 2026.
What is the expense ratio of ITI Pharma and Healthcare Fund?
The expense ratio of ITI Pharma and Healthcare Fund is 2.63% per year.
What is the minimum SIP amount for ITI Pharma and Healthcare Fund?
You can start a SIP in ITI Pharma and Healthcare Fund with ₹3,000 a month.
Is there a lock-in or exit load on ITI Pharma and Healthcare Fund?
Lock-in: None. Exit load: Exit load of 0.50%, if redeemed within 3 months..
How risky is ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund is rated Very High on the SEBI riskometer and belongs to the Sectoral-Pharma category.
Which fund house manages ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund is managed by ITI Mutual Fund, which runs 20 schemes with ₹11,302 Cr under management.